NCT02244229已完成4 期
MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride.
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 403
- 主要终点
- Change from baseline in Symptom Problem Index (SPI) by means of validated patient questionnaire
研究概览
简要总结
Study to evaluate the therapeutic effect of tamsulosin and finasteride in symptomatic BPH patients, two medications indicated in BPH belonging to two different pharmacological classes, as evaluated from the point of view of patient's perception of his pathological condition and of the impact of the disease on general health and quality of life
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 50 Years 至 80 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male out-patients aged 50-80 years
- •IPSS >= 13 at Visit 1
- •Qmax: 4-15 ml/sec at Visit 2
- •Residue urinary volume > 400 ml as evaluated by ultrasonography
- •SPI >= 7 at Visit 2
- •Prostate Specific Antigen (PSA) value < 3 ng/ml at Visit 1, or of 3-10 ng/ml provided that prostate cancer is ruled out on the basis of the usual diagnostic procedures performed at each Centre
- •Written informed consent
排除标准
- •Patients with known history or diagnosis at the time of the screening visit of the following conditions that could influence the end-points of the study:
- •Urological disturbances
- •Medical history of pelvic surgery; palpable bladder at the physical examination, or residue urinary volume > 400 ml; known neurological bladder disorder, bladder neck stenosis, urethral stricture, bladder or prostatic cancer, bladder stone, severe diverticulum of the bladder, symptomatic urinary tract infection during the last month, or recurrent urinary tract infections (more than 2 during the last year); hematuria of unknown origin; diseases that may affect micturition (e.g. diabetes mellitus)
- •Cardiovascular diseases - The following cardiovascular diseases if occurred in the last 6 months:
- •Myocardial infarction
- •Unstable angina
- •Clinically significant ventricular arrhythmias
- •Heart failure (NYHA classes III/IV)
- •Orthostatic hypotension
- •Cerebral stroke
- •Neurological diseases
- •such as senile dementia, multiple sclerosis, Parkinson's disease, psychiatric disturbances, if their severity could have prevented the correct performance of the trial
- •Hepatic or renal insufficiency
- •(Biochemistry values 15% outside normal laboratory ranges and regarded as clinically relevant by investigator)
- •Clinically significant abnormalities in the results of hematologic and biochemical tests performed on blood samples drawn at the screening visit
- •Patients who are taking or have been taking α-blockers for BPH or for hypertension or phytotherapy for BPH in the previous 6 weeks
- •Patients who are taking or have been taking finasteride in the last 6 months
- •Patients who require concomitant drugs which could influence the pharmacodynamic or pharmacokinetic properties of tamsulosin. In particular: alpha-blockers and mixed alpha-beta blockers, alpha- agonists, anti-cholinergics
- •Patient who are or have been taking part in a clinical study in the previous 3 months
- •Patients who have hypersensitivity or allergic reactions to previously prescribed alpha-blocker(s) or to finasteride
- •Patients judged by the investigator to be inappropriate for inclusion in the study
研究组 & 干预措施
Tamsulosin
Experimental
干预措施: Tamsulosin (Drug)
Tamsulosin
Experimental
干预措施: Placebo (Drug)
Finasteride
Active Comparator
干预措施: Finasteride (Drug)
Finasteride
Active Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline in Symptom Problem Index (SPI) by means of validated patient questionnaire
时间窗: Baseline, after 26 weeks of treatment
次要结局
- Change in International Prostatic Symptom Score (IPSS)(up to 52 weeks)
- Number of patients with adverse events(up to 54 weeks)
- Number of patients who withdrew due to inefficacy(up to 52 weeks)
- Change in Qmax by means of free flow uroflowmetry(up to 52 weeks)
- Change in Symptom Problem Index (SPI) - by means of validated patient questionnaire(up to 52 weeks)
- Number of patients with abnormal changes in laboratory parameters(up to 52 weeks)
研究者
相似试验
已完成
1 期
A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.Prostatic HyperplasiaNCT00609596GlaxoSmithKline24
已完成
3 期
Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination TreatmentProstatic HyperplasiaNCT00090103GlaxoSmithKline4,844
已完成
4 期
Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary SymptomsProstatic HyperplasiaNCT02245490Boehringer Ingelheim153
已完成
3 期
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPHBenign Prostate HyperplasiaNCT02390882Hanmi Pharmaceutical Company Limited494
已完成
4 期
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate CancerProstate CancerBenign Prostatic HyperplasiaNCT00375765GlaxoSmithKline40